Emilia Gigliotta

Palermo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience.

Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience.

Journal: Haematologica

Published: March 12, 2026

Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions.

Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions.

Journal: International journal of molecular sciences

Published: February 27, 2026

Monoclonal Gammopathy Prevalence in Newly Diagnosed Prostate Cancer Patients: A Correlative Perspective Observational Study.

Monoclonal Gammopathy Prevalence in Newly Diagnosed Prostate Cancer Patients: A Correlative Perspective Observational Study.

Journal: Cancers

Published: September 01, 2025

Inflammatory Biomarkers for Thrombotic Risk Assessment in Multiple Myeloma Patients on IMiD/aCD38-Based Regimens: Insights from a Prospective Observational Study.

Inflammatory Biomarkers for Thrombotic Risk Assessment in Multiple Myeloma Patients on IMiD/aCD38-Based Regimens: Insights from a Prospective Observational Study.

Journal: Biomolecules

Published: August 31, 2025

An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.

An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.

Journal: Annals of hematology

Published: April 18, 2025

Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response.

Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response.

Journal: Blood neoplasia

Published: April 01, 2025

Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience.

Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience.

Journal: Haematologica

Published: July 24, 2024

Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.

Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.

Journal: European journal of haematology

Published: July 23, 2024

Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients.

Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients.

Journal: Experimental hematology & oncology

Published: June 02, 2024

Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials.

Molecular-Biology-Driven Frontline Treatment for Chronic Lymphocytic Leukemia: A Network Meta-Analysis of Randomized Clinical Trials.

Journal: International journal of molecular sciences

Published: February 23, 2023

Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome.

Ferritin Metabolism Reflects Multiple Myeloma Microenvironment and Predicts Patient Outcome.

Journal: International journal of molecular sciences

Published: February 06, 2023

Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.

Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again.

Journal: Hematology reports

Published: July 02, 2022

Showing 1-12 of 13

Last Updated: 09/26/2026